Abbott Laboratories (NYSE:ABT) Stock Unloaded Sen. Shelley Moore Capito

Senator Shelley Moore Capito (R-West Virginia) recently sold shares of Abbott Laboratories (NYSE:ABT). In a filing disclosed on March 06th, the Senator disclosed that they had sold between $1,001 and $15,000 in Abbott Laboratories stock on February 24th.

Senator Shelley Moore Capito also recently made the following trade(s):

• Sold $1,001 – $15,000 in shares of Accenture (NYSE:ACN) on 2/24/2025.
• Sold $1,001 – $15,000 in shares of Comcast (NASDAQ:CMCSA) on 2/24/2025.
• Sold $1,001 – $15,000 in shares of Apple (NASDAQ:AAPL) on 2/5/2025.
• Purchased $1,001 – $15,000 in shares of Constellation Energy (NASDAQ:CEG) on 2/4/2025.
• Sold $1,001 – $15,000 in shares of Microsoft (NASDAQ:MSFT) on 2/4/2025.
• Sold $1,001 – $15,000 in shares of W.W. Grainger (NYSE:GWW) on 1/17/2025.
• Sold $1,001 – $15,000 in shares of Microsoft (NASDAQ:MSFT) on 1/17/2025.
• Sold $1,001 – $15,000 in shares of BlackRock (NYSE:BLK) on 1/17/2025.
• Sold $1,001 – $15,000 in shares of JPMorgan Chase & Co. (NYSE:JPM) on 1/17/2025.
• Sold $1,001 – $15,000 in shares of Phillips 66 (NYSE:PSX) on 1/17/2025.

Abbott Laboratories Stock Down 2.0 %

ABT stock opened at $134.90 on Friday. Abbott Laboratories has a 52 week low of $99.71 and a 52 week high of $141.23. The company has a market capitalization of $233.97 billion, a price-to-earnings ratio of 17.63, a price-to-earnings-growth ratio of 2.52 and a beta of 0.75. The firm’s 50-day moving average is $124.90 and its two-hundred day moving average is $118.53. The company has a current ratio of 1.60, a quick ratio of 1.14 and a debt-to-equity ratio of 0.32.

Abbott Laboratories (NYSE:ABT) last released its quarterly earnings results on Wednesday, January 22nd. The healthcare product maker reported $1.34 EPS for the quarter, hitting analysts’ consensus estimates of $1.34. Abbott Laboratories had a net margin of 31.95% and a return on equity of 20.74%. The company had revenue of $10.97 billion for the quarter, compared to the consensus estimate of $11.03 billion. During the same period in the previous year, the firm earned $1.19 EPS. Abbott Laboratories’s revenue was up 7.2% on a year-over-year basis. On average, analysts forecast that Abbott Laboratories will post 5.14 earnings per share for the current fiscal year.

Abbott Laboratories Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Thursday, May 15th. Shareholders of record on Tuesday, April 15th will be given a dividend of $0.59 per share. The ex-dividend date is Tuesday, April 15th. This represents a $2.36 dividend on an annualized basis and a dividend yield of 1.75%. Abbott Laboratories’s dividend payout ratio (DPR) is 30.85%.

Insider Activity at Abbott Laboratories

In other Abbott Laboratories news, SVP Eric Shroff sold 562 shares of the business’s stock in a transaction that occurred on Monday, March 3rd. The shares were sold at an average price of $138.17, for a total value of $77,651.54. Following the completion of the sale, the senior vice president now directly owns 31,970 shares of the company’s stock, valued at $4,417,294.90. The trade was a 1.73 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, EVP Andrea F. Wainer sold 949 shares of the business’s stock in a transaction that occurred on Monday, March 3rd. The stock was sold at an average price of $138.17, for a total transaction of $131,123.33. Following the completion of the sale, the executive vice president now directly owns 74,381 shares of the company’s stock, valued at $10,277,222.77. This represents a 1.26 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 25,282 shares of company stock valued at $3,263,348. Corporate insiders own 1.10% of the company’s stock.

Wall Street Analyst Weigh In

ABT has been the topic of a number of recent analyst reports. The Goldman Sachs Group boosted their price target on shares of Abbott Laboratories from $138.00 to $154.00 and gave the stock a “buy” rating in a research report on Tuesday. StockNews.com downgraded shares of Abbott Laboratories from a “strong-buy” rating to a “buy” rating in a report on Wednesday, February 12th. Argus upgraded shares of Abbott Laboratories to a “strong-buy” rating in a report on Tuesday, January 28th. UBS Group boosted their target price on shares of Abbott Laboratories from $146.00 to $148.00 and gave the stock a “buy” rating in a report on Thursday, January 23rd. Finally, Barclays reiterated an “overweight” rating and issued a $158.00 target price (up from $149.00) on shares of Abbott Laboratories in a report on Monday, January 27th. Four research analysts have rated the stock with a hold rating, fourteen have given a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, Abbott Laboratories has a consensus rating of “Moderate Buy” and a consensus price target of $137.19.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the company. Norges Bank purchased a new position in Abbott Laboratories during the fourth quarter valued at approximately $2,373,461,000. T. Rowe Price Investment Management Inc. grew its position in Abbott Laboratories by 383.1% during the fourth quarter. T. Rowe Price Investment Management Inc. now owns 8,358,698 shares of the healthcare product maker’s stock valued at $945,453,000 after purchasing an additional 6,628,310 shares in the last quarter. Raymond James Financial Inc. purchased a new position in Abbott Laboratories during the fourth quarter valued at approximately $635,056,000. Massachusetts Financial Services Co. MA grew its position in Abbott Laboratories by 25.6% during the third quarter. Massachusetts Financial Services Co. MA now owns 13,319,347 shares of the healthcare product maker’s stock valued at $1,518,539,000 after purchasing an additional 2,711,586 shares in the last quarter. Finally, State Street Corp grew its position in Abbott Laboratories by 3.1% during the third quarter. State Street Corp now owns 76,720,429 shares of the healthcare product maker’s stock valued at $8,746,896,000 after purchasing an additional 2,323,807 shares in the last quarter. 75.18% of the stock is owned by hedge funds and other institutional investors.

About Senator Capito

Shelley Moore Capito (Republican Party) is a member of the U.S. Senate from West Virginia. She assumed office on January 3, 2015. Her current term ends on January 3, 2027. Capito (Republican Party) ran for re-election to the U.S. Senate to represent West Virginia. She won in the general election on November 3, 2020. Capito was first elected to the Senate in 2014, becoming the first female U.S. Senator in the state’s history. Prior to serving in the Senate, Capito was a member of the West Virginia House of Representatives from 1997 to 2001 and a member of the United States House of Representatives from 2001 to 2015. At the start of the 116th Congress, Capito was a member of the U.S. Senate committees on Appropriations, Commerce, Science, and Transportation, Environment and Public Works, and Rules and Administration. As of a 2014 analysis of multiple outside rankings, Capito is a more moderate right of center Republican Party vote. As a result, she may break with the Republican Party line more than her fellow members. Capito earned her bachelor’s degree from Duke University. After earning her M.Ed. from the University of Virginia, Capito was a college counselor and then director of an educational information center. She was the only Republican in the West Virginia congressional delegation until the 2010 elections and is the first Republican woman elected to Congress from West Virginia. Capito is a former chairwoman of the Congressional Caucus for Women’s Issues, as well as a member of the Congressional Arts Caucus. After an explosion responsible for the death of 29 coal workers, Capito founded the Congressional Coal Caucus. Prior to her election to the U.S. House, Capito served in the West Virginia House of Delegates.

Abbott Laboratories Company Profile

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière’s disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.